Zidovudine, Lamivudine, and Nelfinavir Concentrations in Amniotic Fluid and Maternal Serum

REFERENCES

• De Cock KM, Fowler MG, Mercier E, de Vincenzi I, Saba J, Hoff E, et al. Prevention of mother-to-child HIVtransmission in resource-poor countries. JAMA. 2000;283:1175–1182.
   PubMed Web of Science ®Google Scholar
• Moodley D, Moodley J, Coovadia H, Gray G, McIntyre J, Hofmyer J, et al., for the South African Intrapartum Nevi-rapine Trial (SAINT) Investigators. A multicenter random-ized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of Human Immu-nodeficiency Virus Type 1. J Infect Dis. 2003;187:725–735.
   PubMed Web of Science ®Google Scholar
• Young AM, Allen CE, Audus KL. Efflux transporters of the human placenta. Adv Drug Deliv Rev. 2003;55:125–132.
   PubMed Web of Science ®Google Scholar
• Gilbert WM, Brace RA. Amniotic fluid volume and normal flows to and from the amniotic cavity. Semin PerinatoL 1993;17:150–157.
   PubMed Web of Science ®Google Scholar
• Remmel RP, Kawle SP, Weller D, Fletcher CV. Simultaneous HPLC assay for quantification of indinavir, ritonavir, and saquinavir in human plasma. Clin Chem. 2000;46:73–81.
   PubMed Web of Science ®Google Scholar
• Fletcher CV, Brundage RC, Remmel RP, Page LM, Weller D, CaIles NR, et al. Pharmacologic characteristics of indina-vir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy. Antimicrob Agents Chemother 2000;44:1029–1034.
   PubMed Web of Science ®Google Scholar
• Mandelbrot L, Peytavin G, Firtion G, Farinotti R. Maternal-fetal transfer and amniotic fluid accumulation of lamivu-dine in Human Immunodeficiency Virus-infected pregnant women. Am J Obstet GynecoL 2001184: 153–158.
   Google Scholar
• Chappuy H, Treluyer JM, Jullien V, Dimet J, Rey E, Fouche M, et al. Maternal-fetal transfer and amniotic fluid accu-mulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected preg-nant women. Antimicrob Agents Chemother. 2004;48: 4332–4336.
   PubMed Web of Science ®Google Scholar
• Parkin NT, Hellmann NS, Whitcomb JM, Kiss L, Chappey C, Petropoulos CJ. Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1. Antimi-crob Agents Chemother 2004;48:437–443.
   PubMed Web of Science ®Google Scholar
• Limoli KL, Trinh LH, Heilek-Snyder GM, Hellmann NS, Petropoulos CJ. Effects of human serum on protease inhibitor activity in a phenotypic drug susceptibility assay (Phenosense HIV). In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections; February 24–28, 2002; Seattle, WA. Abstract 583–T.
   Google Scholar
• Pellegrin I, Breilh D, Montestruc F, Caumont A, Garrigue I, Morlat P, et al. Virologic response to nelfinavir-based regi-mens: Pharmacokinetics and drug resistance mutations (Viraphar study). AIDS. 2002;16:1331–1340.
   PubMed Web of Science ®Google Scholar
• Bardos P, Luthier B, Avenet JM, de Russe J, Muh JP, Soutoul JH, Weill JD. [Variations of the concentrations of certain glycoproteins in maternal serum, fetal serum and amniotic fluid during pregnancy] [in French]. Clin Chim Acta. 1976:66;353–363.
   PubMed Web of Science ®Google Scholar
• Bala S, Seth S, Seth PK. Albumin concentration in human amniotic fluid from normal pregnancies. Acta Paediatr Hung. 1987:28;187–192.
   PubMedGoogle Scholar
• Chappuy J, Treluyer JM, Rey E, Dimet J, Fouche M, et al. Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus. Am J Obstet Gyne-coL 2004;191:558–562.
   PubMed Web of Science ®Google Scholar
• Marzolini C, Rudin C, Decosterd LA, Telenti A, Schreyer A, Biollaz J, Buclin T, and the Swiss Mother & Child HIV Cohort Study. Transplacental passage of protease inhibi-tors at delivery. AIDS. 2002;16:889–893.
   PubMed Web of Science ®Google Scholar
• Mirochnick M, Dorenbaum A, Holland D, Cunningham-Schrader B, Cunningham C, Gelber R, et al. Concentra-tions of protease inhibitors in cord blood after in utero exposure. J Pediatr Infect Dis. 2002;21:835–838.
   PubMed Web of Science ®Google Scholar
• Smit JW, Huisman MT, van Tellingen O, Wiltshire HR, Schinkel AH. Absence of pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J Clin Invest. 1999;104:1441–1447.
   PubMed Web of Science ®Google Scholar
• Huisman MT, Smit JW, Wiltshire HR, Hoetelman RMW, Beijnen JH, Schinkel AH. P-glycoprotein limits oral avail-ability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol PharmacoL 200159: 806–813.
   Google Scholar
• Sudhakaran S, Ghabrail H, Nation RL, Kong DCM, Gude NM, Angus PW, Rayner CR. Differential bidirectional trans-fer of indinavir in the isolated perfused human placenta. Antimicrob Agents Chemother 2005;49:1023–1028.
   PubMed Web of Science ®Google Scholar
• Hirt D, Urien S, Jullien V, Firtion G, Chappuy H, Rey E, et al. Pharmacokinetic modelling of the placental transfer of nelfinavir and its M8 metabolite: A population study using 75 maternal-cord plasma samples. Br J Clin PharmacoL 2007;64:634–644.
   PubMed Web of Science ®Google Scholar
• Gingelmaier A, Kurowski M, Kastner R, Eberle J, Mylonas I, Belohradsky BH, et al. Placental transfer and pharma-cokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. AIDS. 2006;20: 1737–1743.
   PubMed Web of Science ®Google Scholar
• Van Heeswijk RPG, Khaliq Y, Gallicano KD, Bourbeau M, Seguin I, Phillips EJ, Cameron DW. The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum. Clin Pharm Ther 2004;76:588–597.
   PubMed Web of Science ®Google Scholar
• Koukouritaki SB, Manro JR, Marsh SA, Stevens JC, Rettie AE, McCarver DG, Hines RN. Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther 2004;308:965–974.
   PubMed Web of Science ®Google Scholar
• Hakkola J, Pasanen M, Hukkanen J, Pelkonen O, Maenpaa J, Edwards RJ, et al. Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta. Bio-chem PharmacoL 1996;51:403–411.
   PubMed Web of Science ®Google Scholar
• Bonora S, Gonzalez de Requena D, Chiesa E, Maccabruni A, Forleo MA, Vichi F, et al., and the TARGET study group. Transplacental passage of tenofovir and other antiretro-virals at delivery. Presented at: 14th Annual Conference on Retroviruses and Opportunistic Infections; February 25–28, 2007; Los Angeles, CA. Abstract 738a.
   Google Scholar
• St-Pierre MV, Serrano MA, Macia RIR, Dubs U, Hoechli M, Lauper U, et al. Expression of members of the mutidrug resistance protein family in human term placenta. Am J Phsiol Regul Integr Comp Physiol. 2000:279; R1495–1503.
   PubMed Web of Science ®Google Scholar
• Wijnholds J, Moi CAAM, van Deemter L, de Haas M, Scheffer GL, Baas F, et al. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci USA. 2000:97; 7476–7481.
   PubMed Web of Science ®Google Scholar
• Mandelbrot L, Burgard M, Teglas JP, Benifla JL, Kahn C, Blot P, et al. Frequent detection of HIV-1 in the gastric aspirates of neonates born to HIV-infected mothers. AIDS. 1999;13:2143–2149.
   PubMed Web of Science ®Google Scholar